PIK3CA and head and neck squamous cell carcinoma: Recently, many clinical trials on HNSCC patients are ongoing to evaluate the efficiency of PI3K/AKT/mTOR inhibitors, often using rapamycin analogs, and these show partially promising treatment responses [66,67,68].